CSL LIMITED - News & Media

1.32%

$208.53

Market Cap $101.0B

Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

MEMPHASYS LIMITED

Many are concerned about global falling birthrates. This diverse stock has solutions. Here, then, one can’t afford to miss perusing what ASX-listed fertility tech healthcare smallcap Memphasys Ltd (ASX:MEM) can offer the world.

Articles & Videos

CSL price walloped -10% on widespread 'cost-saving' job cuts, Seqirus spinoff plans

Earnings day hasn’t quite been a shining one for CSL Ltd (ASX:CSL), with the $117 billion biotechnology bluechip unveiling plans to trim its global workforce by as much as 15% as it looks to save $550 million annually.Listen to the HotCopper podcast for in-depth discussions and in...

19 Aug 2025 11:36 (AEST)

Biotech stocks that survived April 2 feel the heat of Trump's new pharma threat

If you thought a 104% tariff on China was bad enough, Trump’s found another way to make the markets about himself @ now confirming major tariffs on pharmaceuticals.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout th...

09 Apr 2025 13:24 (AEST)

CSL survives a brutal sell-off but dips on US tariff response as investors eye pharma risk

CSL Ltd (ASX:CSL) has seen shares fall nearly half a percent in afternoon trades on Thursday as the company responds to Trump's US tariffs.

03 Apr 2025 13:27 (AEDT)

CSL up 6% on strong demand for CSL Behring business

CSL Ltd has reported rises in profit and revenue for the first half of the 2025 fiscal year, with particular growth in its CSL Behring arm

11 Feb 2025 09:36 (AEDT)

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $208.53		Change 2.720(1.32%)		Mkt cap ! $101.0B

Open	High	Low	Value	Volume
$206.00	$210.12	$205.90	$154.1M	718.3K

Buyers (Bids)

No.	Vol.	Price($)
13	119	$208.52

Sellers (Offers)

Price($)	Vol.	No.
$208.54	80	8

View Market Depth

No.	Vol.	Price($)
7	201	208.430
5	68	208.420
5	57	208.410
4	93	208.400
4	68	208.390

Price($)	Vol.	No.
208.470	36	3
208.480	31	2
208.490	44	3
208.500	91	5
208.510	99	6

Last trade - 14.06pm 12/09/2025 (20 minute delay)


Last $208.43		Change 2.720 ( 1.68 %)
Open	High	Low	Volume
$206.20	$210.10	$205.95	93720
Last updated 14.24pm 12/09/2025 ?

CSL (ASX) Chart